Source-grounded facts extracted from ARDELYX, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ARDELYX, INC. shareholders approved Approval of the Equity Plan Amendment at the 2026-06-16 meeting.
“Proposal No. 5 - Approval of the Equity Plan Amendment The Company’s stockholders approved the Equity Plan Amendment. Votes For Votes Against Abstentions Broker Non-Votes 77,395,305 69,720,789 674,708 41,417,148”
ARDELYX, INC. shareholders approved Ratification of Appointment of Independent Registered Accounting Firm at the 2026-06-16 meeting.
“Proposal No. 4 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment, by the Audit Committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026. Votes For Votes Against Abstentions Broker Non-Votes 186,182,340 2,012,970 1,012,640 —”
ARDELYX, INC. shareholders approved Approval, on a non-binding, advisory basis, of the Say-On-Frequency proposal at the 2026-06-16 meeting.
“Proposal No. 3 - Approval, on a non-binding, advisory basis, of the Say-On-Frequency proposal The Company’s stockholders approved, on a non-binding, advisory basis, the frequency of a Say-On-Pay vote occurring every one (1) year. One Year Two Years Three Years Abstentions Broker Non-Votes 141,539,889 671,451 3,426,669 2,152,793 41,417,148”
ARDELYX, INC. shareholders approved Approval, on a non-binding, advisory basis, of the Say-On-Pay proposal at the 2026-06-16 meeting.
“Proposal No. 2 - Approval, on a non-binding, advisory basis, of the Say-On-Pay proposal The Company’s stockholders approved, on a non-binding, advisory basis, the Say-On-Pay proposal. Votes For Votes Against Abstentions Broker Non-Votes 137,617,786 9,413,395 759,621 41,417,148”
ARDELYX, INC. shareholders approved Election of Directors at the 2026-06-16 meeting.
“Proposal No. 1 - Election of Directors The Company’s stockholders elected the Class III director nominees below to the Company’s Board to hold office until the 2029 Annual Meeting of Stockholders or until their successors are elected. Class II Director Nominees Votes For Votes Withheld Broker Non-Votes Robert Bazemore 143,174,322 4,616,480 41,417,148 Muna Bhanji, R.Ph 121,228,081 26,562,721 41,417,148 Richard Rodgers 141,495,737 6,295,065 41,417,148”
ARDELYX, INC. reported quarter ended March 31, 2026 results: revenue Total product revenue for the quarter ended March 31, 2026 was $93.4 million, net income Net loss for the quarter ended March 31, 2026 was $37.6 million, EPS $(0.15) per share.
“Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update Q1 2026 total product revenue of $93.4 million, reflecting 38% growth year-over-year”
ARDELYX, INC.: Board adopted Second Amended and Restated Bylaws updating procedural and disclosure requirements for shareholder nominations and proposals, quorum provisions, stockholder list requirements, and adding a forum selection provision (effective 2025-08-01).
“On August 1, 2025, the Board of Directors (the “Board”) of the Company approved and adopted the Company’s Second Amended and Restated Bylaws (as amended and restated, the “Bylaws”), effective immediately.”
Merdad Parsey was appointed as Director at ARDELYX, INC..
“On April 28, 2025, the Company appointed Merdad Parsey, M.D., Ph.D, as a member of the Board of Directors (the “Board”) of Ardelyx, Inc., a Delaware corporation (the “Company”), effective immediately”
Robert Felsch changed role as senior financial advisor at ARDELYX, INC..
“Mr. Felsch will remain with the Company and will transition to a senior financial advisor role within the Company”
Joseph Reilly was appointed as Principal Accounting Officer at ARDELYX, INC..
“The Company has appointed Joseph Reilly to replace Robert Felsch in his capacity as the Company’s Principal Accounting Officer effective November 15, 2024.”
ARDELYX, INC. reported financial results for first quarter ended March 31, 2024.
“On May 2, 2024, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.”
ARDELYX, INC. incurred term loan of $50.0 million with SLR Investment Corp. as collateral agent and the lenders listed in the agreement at 4.25% plus a SOFR value equal to 0.022% plus the 1-month CME Term SOFR reference maturing March 1, 2027.
“On March 1, 2024, Ardelyx, Inc. (the we, us, our) received $50.0 million of funding (Term C Loan) pursuant to the loan and security agreement entered into in February 2022 by and between us and SLR Investment Corp. as collateral agent (Agent) and the lenders listed in the agreement (collectively, the Lenders), and as amended in August 2022, February 2023 and October 2023 (collectively, the 2022 Loan Agreement).”
ARDELYX, INC. updated its the fourth quarter of 2023 guidance (initiated).
“During the fourth quarter of 2023, U.S. net product sales revenue was $28.1 million, reflecting 26% growth compared to the third quarter of 2023.”
ARDELYX, INC. reported the year ended December 31, 2023 results: revenue Total revenues for the year ended December 31, 2023 were $124.5 million. Guidance initiated.
“Total revenues for the year ended December 31, 2023 were $124.5 million, compared to $52.2 million in total revenues in 2022, reflecting increased net product sales, licensing revenues and product supply revenue.”
ARDELYX, INC. reported the full year ended December 31, 2023 results: revenue approximately $80 million.
“On January 8, 2024, Ardelyx, Inc. (the “Company”) announced unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2023, and approximately $80 million for the full year ended December 31, 2023”
ARDELYX, INC. reported the fourth quarter ended December 31, 2023 results: revenue approximately $28 million.
“On January 8, 2024, Ardelyx, Inc. (the “Company”) announced unaudited U.S. net product sales revenue of IBSRELA ® (tenapanor) of approximately $28 million for the fourth quarter ended December 31, 2023”
Geoffrey A. Block resigned as Director at ARDELYX, INC..
“On November 13, 2023, Geoffrey A. Block, M.D. notified the Board of Directors (the “Board”) of Ardelyx, Inc. (the “Company”) of his decision to resign from the Board and the Nominating and Governance Committee of the Board, effective on November 13, 2023.”
ARDELYX, INC. updated its the third quarter ended September 30, 2023 guidance (reaffirmed).
“On October 31, 2023, Ardelyx, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023.”
ARDELYX, INC. amended Third Amendment to Loan and Security Agreement with SLR Investment Corp. valued at $50 million (effective 2023-10-17).
“On October 17, 2023, Ardelyx, Inc. (the “Company”) entered into a Third Amendment to Loan and Security Agreement (the “Third Amendment”), by and among the Company, as borrower, SLR Investment Corp. (“SLR”), as collateral agent and the lenders party thereto, which amends the Company’s Loan and Security Agreement, dated February 23, 2022.”
ARDELYX, INC. reported second quarter ended June 30, 2023 results: revenue $22.3 million. Guidance raised.
“for IBSRELA were $18.3 million during the quarter ended June 30, 2023, compared to $1.6 million for the quarter ended June 30, 2022. Total revenues for the second quarter were $22.3 million, which included $4.0 million of product supply and licensing related revenue compared to $1.0 million in product supply and licensing related revenue in the same period in 2022.”
ARDELYX, INC.: Increased authorized shares of common stock from 300,000,000 to 500,000,000 (effective 2023-06-16).
“On June 16, 2023, Ardelyx, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Charter Amendment”) of its Amended and Restated Certificate of Incorporation to increase the authorized number of shares of the Company’s common stock from 300,000,000 to 500,000,000 shares.”
ARDELYX, INC. shareholders approved Ratification of Selection of Independent Registered Accounting Firm at the 2023-06-15 meeting.
“Proposal No. 4 - Ratification of Selection of Independent Registered Accounting Firm The Company’s stockholders ratified the selection, by the Audit Committee of the Board, of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023. Votes For Votes Against Abstentions Broker Non-Votes 152,059,458 3,247,809 914,924 —”
ARDELYX, INC. shareholders approved Approval, on a non-binding, advisory basis, of the Say-On-Pay proposal at the 2023-06-15 meeting.
“Proposal No. 3 - Approval, on a non-binding, advisory basis, of the Say-On-Pay proposal The Company’s stockholders approved, on a non-binding, advisory basis, the Say-On-Pay proposal. Votes For Votes Against Abstentions Broker Non-Votes 91,624,106 14,569,831 1,612,753 48,415,501”
ARDELYX, INC. shareholders approved Approval of the Amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 500,000,000 at the 2023-06-15 meeting.
“Proposal No. 2 - Approval of the Amendment to our Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 500,000,000 The Company’s stockholders approved the proposal to amend the Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 500,000,000. Votes For Votes Against Abstentions Broker Non-Votes 117,358,621 38,616,363 247,207 48,415,501”
ARDELYX, INC. shareholders approved Election of Directors at the 2023-06-15 meeting.
“The Company’s stockholders elected the Class III director nominees below to the Company’s Board of Directors (the “Board”) to hold office until the 2026 Annual Meeting of Stockholders or until their successors are elected. Class III Director Nominees Votes For Votes Withheld Broker Non-Votes Robert Bazemore 89,887,627 17,919,063 48,415,501 Muna Bhanji, R.Ph 89,774,352 18,062,338 48,415,501 Richard Rodgers 87,334,118 20,472,572 48,415,501”
ARDELYX, INC. reported the quarter ended March 31, 2023 results: revenue $11.4 million, net income $26.8 million, EPS $(0.13) per share.
“EX-99.1 (EX-99.1) --- Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update Continued successful launch of IBSRELA, with Q1 net product sales of $11.4 million XPHOZAH New Drug Application resubmitted on April 17, 2023 Company ends Q1 with over $130 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time”
ARDELYX, INC. reported financial results for fourth quarter and full year ended December 31, 2022.
“Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales”
ARDELYX, INC. amended credit facility with SLR Investment Corp., as collateral agent, and the lenders listed on Schedule 1.1 to the Loan Agreement at 7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% pl.
“On February 9, 2023, we entered into a second amendment (the “Second Amendment”) to our loan and security agreement (the “Loan Agreement”) with SLR Investment Corp., as collateral agent (the “Agent”), and the lenders listed on Schedule 1.1 to the Loan Agreement (collectively the “Lenders”).”
ARDELYX, INC. amended Second Amendment with SLR Investment Corp., as collateral agent, and the lenders listed on Schedule 1.1 to the Loan Agreement (effective 2023-02-09).
“On February 9, 2023, we entered into a second amendment (the “Second Amendment”) to our loan and security agreement (the “Loan Agreement”) with SLR Investment Corp., as collateral agent (the “Agent”), and the lenders listed on Schedule 1.1 to the Loan Agreement (collectively the “Lenders”).”
ARDELYX, INC. entered into Sales Agreement with Jefferies LLC valued at up to $150.0 million (effective 2023-01-18).
“On January 18, 2023, Ardelyx, Inc. (the “Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may offer and sell shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $150.0 million from time to time, through an “at the market offering” program under which Jefferies will act as sales agent.”
ARDELYX, INC. reported the fiscal quarter ended September 30, 2022 results: net income Net loss for the quarter ended September 30, 2022 was $22.9 million, or $(0.14) per share, EPS $(0.14) per share.
“On November 3, 2022, Ardelyx, Inc. (the “Company”) announced its financial results for the fiscal quarter ended September 30, 2022.”
Justin Renz changed role as Chief Financial Officer at ARDELYX, INC..
“Effective upon Mr. Felsch’s appointment as Chief Accounting Officer, Justin Renz, the Company’s Chief Financial Officer, Principal Accounting Officer and Treasurer will no longer serve as Principal Accounting Officer, but will continue to serve as the Company’s Chief Financial Officer and Treasurer.”
Robert Felsch was appointed as Chief Accounting Officer at ARDELYX, INC..
“On March 10, 2022, Ardelyx, Inc. (the “Company”) appointed Robert Felsch as the Company’s Chief Accounting Officer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.